GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

The Canadian Journal of Infectious Diseases & Medical Microbiology, published by HINDAWI LTD, is a pioneering open-access journal focused on advancing the fields of infectious diseases and medical microbiology, with its commitment to disseminating innovative research since 2004. With the ISSN 1712-9532 and E-ISSN 1918-1493, the journal is recognized for its high-caliber contributions, achieving a 2023 Q2 ranking in Infectious Diseases and a Q3 ranking in Medical Microbiology, as per the prestigious Scopus rankings. Offering a global platform for researchers and clinicians, the journal is crucial for fostering collaboration and sharing knowledge across borders, emphasizing its role as a significant resource for addressing pressing health challenges. With an HIndex that indicates an increasing influence in the scientific community, the journal maintains its focus on impactful studies that inform clinical practices and policies, while also being available to a diverse audience through its open-access format. Based in Egypt, the journal looks forward to continuing its impact up to 2024 and beyond, serving as a vital forum for scientific exchange and practical applications in the fight against infectious diseases.

Welcome to the International Journal of Medical Microbiology, a leading publication in the field of microbiological research and infectious diseases, offered by Elsevier GmbH. Established in 2000, this esteemed journal provides a scholarly platform for the presentation of high-quality research, reviews, and innovations that bridge medical microbiology and clinical applications. With an impressive impact factor positioning it within the Q1 category across multiple disciplines, including Infectious Diseases, Microbiology, and Medicine, the journal is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of microbial pathogenesis, diagnostics, and therapeutics. The International Journal of Medical Microbiology is committed to open access, promoting the dissemination of knowledge and accessibility for researchers, professionals, and students worldwide. Based in Munich, Germany, the journal continues to play a vital role in the global scientific community, fostering collaborations and inspiring future innovations in the fight against infectious diseases.

BMC Microbiology is a leading open access journal published by BMC, dedicated to advancing the field of microbiology since its inception in 2001. With an ISSN of 1471-2180, this journal provides a vital platform for researchers, professionals, and students to share and access high-quality research and innovation in both general and medical microbiology. Based in the United Kingdom, BMC Microbiology holds a commendable Q2 ranking in both various microbiological categories according to the 2023 Scopus rankings, indicating its strong influence in the microbiological community, with a rank of #47 out of 140 in Medical Microbiology and #62 out of 182 in general Microbiology. The journal's commitment to open access ensures that groundbreaking research is freely available to facilitate collaboration and knowledge sharing among the global community of microbiologists. With a focus on publishing original research, reviews, and case studies, BMC Microbiology plays a critical role in disseminating information that can impact health and environmental conditions around the world.

Medical Microbiology and Immunology is a renowned journal published by Springer, serving as a pivotal resource in the fields of microbiology and immunology. Established in 1971 and continuing its legacy through 2024, this journal features cutting-edge research and reviews that address critical advancements and challenges within these dynamic fields. With an impressive impact factor and a robust ranking, including Q1 categories in both Microbiology (medical) and Immunology, it stands at the forefront of scholarly communication, ranking 21st out of 140 in the realm of Medical Microbiology. Researchers and professionals are encouraged to explore a variety of studies that delve into the interactions between microorganisms and the immune system, making it an essential resource for anyone fascinated by these interconnected realms of health sciences. Although not open access, the journal is widely accessible through institutional libraries, ensuring that significant findings reach a global audience. The University of New York Plaza serves as its operational hub in the USA, reinforcing its international influence and dedication to advancing knowledge in microbiology and immunology.

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.

Current Clinical Microbiology Reports, published by Springer, is a leading international journal dedicated to advancing the field of clinical microbiology. With a focus on the diagnosis, treatment, and prevention of infectious diseases, this journal serves as a vital resource for researchers, medical professionals, and students engaged in microbiological studies. As a testament to its quality and influence, it holds an impressive impact factor and ranks in the Q1 category in both Infectious Diseases and Microbiology (medical), reflecting its prominent standing in the scholarly community. Additionally, it features a commendable Scopus ranking, placing it in the 77th percentile for Medicine - Infectious Diseases and the 69th percentile for Medicine - Microbiology (medical). With contributions spanning over a decade, from 2014 to 2024, the journal continues to publish high-quality research articles that shape the future of clinical practices and public health policies. While access options are variable, the journal's commitment to open dialogue and dissemination of knowledge makes it a pivotal platform for those passionate about tackling microbial challenges in healthcare.

MICROBES AND INFECTION is a premier academic journal published by Elsevier, dedicated to the dynamic fields of immunology, infectious diseases, and microbiology. With a notable impact factor reflective of its high-quality research contributions, the journal is categorized in the Q2 quartile across these fields as of 2023. Based in France and operating since 1999, MICROBES AND INFECTION offers a platform for researchers, professionals, and students to disseminate and access cutting-edge findings that drive innovation and knowledge in microbial and infectious disease research. The journal is ranked impressively within the Scopus database, securing ranks such as #16 in Microbiology and #33 in Infectious Diseases, underscoring its high relevance in the scientific community. Subscribers to the journal can expect an array of articles, reviews, and original research, all designed to advance understanding and improve clinical practices in the fight against infectious agents. With its ongoing commitment to open access options, MICROBES AND INFECTION continues to foster global collaboration and information sharing in the pursuit of addressing pressing microbiological challenges.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.